These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 29884817)

  • 1. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.
    Singanayagam A; Glanville N; Girkin JL; Ching YM; Marcellini A; Porter JD; Toussaint M; Walton RP; Finney LJ; Aniscenko J; Zhu J; Trujillo-Torralbo MB; Calderazzo MA; Grainge C; Loo SL; Veerati PC; Pathinayake PS; Nichol KS; Reid AT; James PL; Solari R; Wark PAB; Knight DA; Moffatt MF; Cookson WO; Edwards MR; Mallia P; Bartlett NW; Johnston SL
    Nat Commun; 2018 Jun; 9(1):2229. PubMed ID: 29884817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.
    Singanayagam A; Glanville N; Cuthbertson L; Bartlett NW; Finney LJ; Turek E; Bakhsoliani E; Calderazzo MA; Trujillo-Torralbo MB; Footitt J; James PL; Fenwick P; Kemp SV; Clarke TB; Wedzicha JA; Edwards MR; Moffatt M; Cookson WO; Mallia P; Johnston SL
    Sci Transl Med; 2019 Aug; 11(507):. PubMed ID: 31462509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral immunity is impaired in COPD patients with frequent exacerbations.
    Singanayagam A; Loo SL; Calderazzo M; Finney LJ; Trujillo Torralbo MB; Bakhsoliani E; Girkin J; Veerati P; Pathinayake PS; Nichol KS; Reid A; Footitt J; Wark PAB; Grainge CL; Johnston SL; Bartlett NW; Mallia P
    Am J Physiol Lung Cell Mol Physiol; 2019 Dec; 317(6):L893-L903. PubMed ID: 31513433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.
    Finney LJ; Glanville N; Farne H; Aniscenko J; Fenwick P; Kemp SV; Trujillo-Torralbo MB; Loo SL; Calderazzo MA; Wedzicha JA; Mallia P; Bartlett NW; Johnston SL; Singanayagam A
    J Allergy Clin Immunol; 2021 Feb; 147(2):510-519.e5. PubMed ID: 33068560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.
    Mallia P; Footitt J; Sotero R; Jepson A; Contoli M; Trujillo-Torralbo MB; Kebadze T; Aniscenko J; Oleszkiewicz G; Gray K; Message SD; Ito K; Barnes PJ; Adcock IM; Papi A; Stanciu LA; Elkin SL; Kon OM; Johnson M; Johnston SL
    Am J Respir Crit Care Med; 2012 Dec; 186(11):1117-24. PubMed ID: 23024024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
    Morjaria JB; Rigby A; Morice AH
    Lung; 2017 Jun; 195(3):281-288. PubMed ID: 28255905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired type I and type III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells.
    Vareille M; Kieninger E; Alves MP; Kopf BS; Möller A; Geiser T; Johnston SL; Edwards MR; Regamey N
    Thorax; 2012 Jun; 67(6):517-25. PubMed ID: 22213737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoids impair type I IFN signalling and enhance rhinovirus replication.
    Marcellini A; Swieboda D; Guedán A; Farrow SN; Casolari P; Contoli M; Johnston SL; Papi A; Solari R
    Eur J Pharmacol; 2021 Feb; 893():173839. PubMed ID: 33359650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: a randomized study.
    Prazma CM; Gern JE; Weinstein SF; Prillaman BA; Stempel DA
    Respir Med; 2015 Oct; 109(10):1280-6. PubMed ID: 26289742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining critical roles for NF-κB p65 and type I interferon in innate immunity to rhinovirus.
    Bartlett NW; Slater L; Glanville N; Haas JJ; Caramori G; Casolari P; Clarke DL; Message SD; Aniscenko J; Kebadze T; Zhu J; Mallia P; Mizgerd JP; Belvisi M; Papi A; Kotenko SV; Johnston SL; Edwards MR
    EMBO Mol Med; 2012 Dec; 4(12):1244-60. PubMed ID: 23165884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluticasone propionate on virus-induced airways inflammation and anti-viral immune responses in mice.
    Singanayagam A; Glanville N; Bartlett N; Johnston S
    Lancet; 2015 Feb; 385 Suppl 1():S88. PubMed ID: 26312910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
    Tashkin DP; Miravitlles M; Celli BR; Metzdorf N; Mueller A; Halpin DMG; Anzueto A
    Respir Res; 2018 Oct; 19(1):196. PubMed ID: 30290801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pinellia ternata Attenuates Mucus Secretion and Airway Inflammation after Inhaled Corticosteroid Withdrawal in COPD Rats.
    Du W; Su J; Ye D; Wang Y; Huang Q; Gong X
    Am J Chin Med; 2016; 44(5):1027-41. PubMed ID: 27430907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Nannini LJ; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Karner C; Cates CJ; Evans DJ
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD007033. PubMed ID: 22161409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A; Jones PW; Dalvi PS; McAulay K; McIver T; Dissanayake S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.
    Nannini LJ; Poole P; Milan SJ; Kesterton A
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006826. PubMed ID: 23990350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials.
    Yang M; Du Y; Chen H; Jiang D; Xu Z
    Int Immunopharmacol; 2019 Dec; 77():105950. PubMed ID: 31629940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.